Corcept Therapeutics (NASDAQ:CORT) Cut to "Buy" at StockNews.com
StockNews.com lowered shares of Corcept Therapeutics (NASDAQ:CORT – Free Report) from a strong-buy rating to a buy rating in a report published on Friday morning. Several other brokerages have also weighed in on CORT. Truist Financial increased their price objective on shares of Corcept Therapeutics from $42.00 to $44.00 and gave the stock a buy […]